EHOC 2019

Oncology Program


8 OCTOBER 2019
     
10.00 - 12.00 Cancer Immunotherapy in Lung Cancer Course Başak Oyan Uluç - Berksoy Sahin
13.20 - 13.30 OPENING REMARKS - Berksoy Sahin, Jean - Francois Rossi
13.30 - 15.00 SESSION I - PRECISION AND MOLECULAR ONCOLOGY CHAIRS: Uğur Yılmaz
13.30 - 13.55 Touching Cell Cyle and DNA Repairing: CDK Inhibitors and PARP Inhibitors in Solid Tumors Uğur Yılmaz
13.55 - 14.20 The Bio-Informatics of Precision Cancer Medicine Tariq Mughal
14.20 - 14.45 How Do Molecular Panels Help Me Make Clinical Decisions About My Patients? Prasad Adusumilli
14.45 - 15.00 Q & A
15.00 - 15.30 COFFEE BREAK
15.30 - 18.00 SESSION II - IMMUNE ONCOLOGY (BASIC) CHAIRS: Jean-Francois Rossi, Martin Villalba , Nikolay Tupitsyn, Berksoy Sahin
15.30 - 15.55 Precision Immune Medicine in cancer Jean-Francois Rossi
15.55 - 16.20 Glycan-specific natural antibodies : from diagnosis to threrapy in cancer Nikolay Tupitsyn
16.20- 16.45 Natural Killer Cells in Oncology Martin Villalba
16.45 - 17.10 Cancer Vaccine : A New Therapeutic Way Patrick Frayssinet
17.10 - 17.35 Concluding Remarks in Immune Therapy Jean-Francois Rossi, Martin Villalba , Nikolay Tupitsyn
17.35 - 18.00 Q & A

9 OCTOBER 2019
     
08.30 - 10.00 SESSION III - IMMUNE ONCOLOGY (CLINIC) CHAIRS: Jean-Francois Rossi, Berksoy Sahin
08.30 - 08.55 Allogenic Transplantation as a Model for Immune Therapy in Oncology Patrice Céballos
08.55 - 09.20 mAb Biosimilars Bülent Gümüşel
09.20 - 09.45 CAR T Therapy for Solid Tumors Prasad Adusumilli
09.45 - 10.00 Q & B
10.30 - 12.00 SESSION IV - HEAD AND NECK CANCER CHAIRS: Musa Altun, Rasim Meral
10.30 - 10.55 HPV-Associated Head/Neck Cancer: New Stagings and New Treatments Kübra Özkaya Toraman
10.55 - 11.20 Tumor-Related Factors Warranting Adjuvant Postoperative Therapy in Head and Neck Cancer  Musa Altun
11.20 - 11.45 p16-Negative Advanced Head and Neck Cancer Bora Basaran
11.45 - 12.00 Q & A
12.00 - 13.00 LUNCH BREAK
13.00 - 14.30 SESSION V - NON-SMALL CELL LUNG CANCER CHAIRS: Perran Fulden Yumuk
13.00 - 13.25 Sequencing Agents in the Management of EGFR Mutation Positive Non-Small Cell Lung Cancer Mustafa Erman
13.25 - 13.50 Management of ALK Non-Small Cell Lung Cancer Through First and Subsequent Lines of Therapy Fulden Yumuk
13.50 - 14.15 Immunotherapy in Small and Non-small Cell Lung Cancer; The Role of Immune Checkpoint Inhibitors in Frontline and Beyond Frontline Therapy Başak Oyan Uluç
14.15 - 14.30 Q & A
14.30 - 15.00 COFFEE BREAK
15.00 - 16.30 SESSION VI - EARLY BREAST CANCER CHAIRS: Ozlem Er - Hasan Şenol Coşkun
15.00 - 15.25 Challenging Adjuvant Therapy in HER2+ Breast Cancer: Escalating or De-escalating ? Çağatay Arslan
15.25 - 15.50 Evolving Approaches in Systemic Therapy for Triple-Negative Breast Cancer in Neoadjuvant and Adjuvant Settings Ozlem Er
15.50 - 16.15 Adjuvant Therapy in ER+ HER2- Breast Cancer: Chemotherapy or Not? Mehmet Ali Kaplan
16.15 - 16.30 Q & A
16.30 - 18.00 SESSION VII - COLORECTAL CANCER CHAIRS: Mahmut Gümüş
16.30 - 16.55 Is Shortening the Duration of Adjuvant Treatment is Eligible in Early Staged Colon Cancer? Ece Esin
16.55 - 17.20 Is Tumor Sideness, Biomarkers or Molecular Subtype Classification More Predictive for the Treatment of Unresectable Metastatic Colon Cancer? Gökhan Demir
17.20 - 17.45 Systemic Therapy for Potentially Resectable Metastatic Rectal Cancer Dilek erdem
17.45 - 18.00 Q & A

10 OCTOBER 2019
     
08.30 - 11.00 SESSION VIII - NON - COLORECTAL TUMORS CHAIRS: Şuayib Yalçın, Özlem Er
08.30 - 08.55 New (neo-)adjuvant Standards of Care in Gastro-esophageal Cancer Mehmet Artaç
08.55 - 09.20 What is Changed in the Treatment of Biliary Tract Cancer? Fatih Köse
09.20 - 09.45 Has Sorafenib Still Been the Real Winner Against New Generation TKIs and Immune Checkpoint Inhibitors in HCC? Şahin Laçin
09.45- 10.10 Treatment for recurrent disease following Adjuvant treatment of GIST Maxim Nikulin
10.10 - 10.35 Metastatic Well-Differentiated Gastrointestinal Neuroendocrine (Carcinoid) Tumors: Systematic Therapy Options Alexander Kuzminov
10.35 - 11.00 Q & A
11.00 - 11.30 COFFEE BREAK
11.30 - 13.00 SESSION IX - ADVANCED / METASTATIC BREAST CANCER CHAIRS: Berna Öksüzoğlu, Bülent Orhan
11.30 - 11.55 Optimizing Therapy for ER-Positive Metastatic Breast Cancer Sema Sezgin Göksu 
11.55 - 12.20 Overcoming Resistance in HER2+ Metastatic Breast Cancer Sernaz Uzunoğlu
11.20 - 12.45 Shining Side of the Moon; PARP Inhibitors in Triple Negative Breast Cancer Ömer Dizdar
12.45 - 13.00 Q & A
13.00 - 14.00 LUNCH BREAK
14.00-16.00 SESSION X - URO-ONCOLOGY CHAIRS: Mustafa Erman
14.00 - 14.25 Approach to Stage I Testicular Cancer: Who Needs Treatment and Which One? Ömer Dizdar
14.25 - 14.50 Treatment of Cisplatin-Ineligible Metastatic Bladder Cancer Aziz Karaoğlu
14.50 - 15.15 What is the Role and Best Sequencing of the New Generation Hormonal Agents in the Treatment of Both Hormone Sensitive and Resistant Metastatic Prostate Cancer? Mustafa Erman
15.15 - 15.40 Perioperative Systemic Therapy for Localized Renal Cell Carcinoma: To Treat or Not to Treat ? Çağatay Arslan
15.40 - 16.00 Q & A
16.00 - 17.30 SESSION XI - SKIN CANCER CHAIRS: İsmail Çelik - Tarkan Yetişyiğit
16.00 - 16.25 Update on neoadjuvant/adjuvant treatment of melanoma: Hande Turna
16.25 - 16.50 Markers for immune checkpoint inhibitor resistance Selçuk Seber
16.50 - 17.15 The evolution of metastatic melanoma treatment. What’s next? Dilek Erdem
17.15 - 17.30 Q & A
17.30 - 19.00 SESSION XII - SARCOMA CHAIRS: Berksoy Şahin
17.30 - 17.55 Molecular and morphological diagnosis in bone and soft tissue tumors Marco Gambarotti
17.55 - 18.20 Small round cell tumors Kıvılcım Eren Erdoğan
18.20 - 18.45 Can We Ever Have a Specific Treatment for Every 50 Subtypes of Soft Tissue Sarcoma? Çiğdem Usul Afşar
18.45 - 19.00 Q & A
19.00 CLOSING